Our History
Oncology Reimbursement Management (ORM) is a consulting company founded in July 2009 by Ron Schleif and Bruce Edelen. Located in Indianapolis, ORM focuses its efforts exclusively within oncology pricing, access, and reimbursement. Key oncology stakeholders are constantly trying to optimize how they relate to treatment pricing, access, and reimbursement, and ORM believes having any broader focus would begin to limit the value clients receive from us in dealing with issues so critical to their success.
In working with pharmaceutical and biotech companies, providers, payers, consultants to payers, group purchasing organizations (GPOs), distributors, and professional associations, ORM leverages its experience and expertise to provide insights and direction that enable organizations to achieve their goals. Ultimately, cancer patients receive optimal access to the treatments they require when all key stakeholders are aligned in the delivery of these treatments.
Bruce Edelen
Bruce Edelen has over 30 years of experience in the pharmaceutical industry, 28 of them gleaned at Eli Lilly and Company. Nearly half of Bruce's experience at Lilly was in oncology roles that included sales management, sales training, HR, sales operations, pricing, and reimbursement/access. Bruce developed and managed the oncology reimbursement team at Lilly for over 8 years. He was instrumental in developing the pricing and contracting strategy for oncology marketed products, including Gemzar and Alimta, during his tenure. Bruce also played a pivotal role in the pricing, reimbursement, and access strategies developed for pipeline oncology products. He is known throughout the oncology marketplace for his knowledge and relationships in the oncology reimbursement marketplace. Bruce has a BA in psychology from Miami University.
Ron Schleif
Ron Schleif has over 30 years of experience in health care--5 years as a practicing pharmacist and 25 years with Eli Lilly and Company. Ron’s years at Lilly were in management/senior management roles within strategy development, brand management, sales management, business development and Six Sigma. Prior to the launch of Gemzar in 1995, Ron created Lilly Oncology’s first global strategic plan and then went on to lead the US oncology marketing and sales organizations, taking Gemzar from $60mm in sales to over $600mm. Most recently, Ron helped create and led the Six Sigma initiative at Lilly, both as a black belt and consultant. Specific initiatives included eliminating inefficiencies within oncology patient assistance programs, improving the timeliness of rebate payments through GPOs, and improving sales revenues by increasing the effectiveness of sales organizations. Ron has a BS in pharmacy from Washington State University and an MBA from UCLA.